Skip to main content

Table 2 Characteristics of all patients by endotype assignment at day 1

From: Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

 

All patients

(N = 393)

Inflammopathic

(N = 101)

Adaptive

(Ν = 148)

Coagulopathic

(Ν = 144)

p

Age, years, mean (SD)

62 (12)

62 (12)

61 (12)

63 (12)

0.477

Male sex, n (%)

232 (59.0)

62 (61.4)

83 (56.1)

87 (60.4)

0.645

Body mass index, mean (SD)

29.9 (5.6)

29.2 (5.5)

30.7 (5.6)

29.6 (5.8)

0.058

Charlson’s comorbidity index, mean (SD)

2.2 (1.5)

2.3 (1.6)

2.1 (1.4)

2.3 (1.7)

0.671

SOFA score, mean (SD)

2.6 (1.1)

2.7 (1.2)

2.3 (1.0)*,#

2.7 (1.0)

0.006

Comorbidities, n (%)

 Type 2 diabetes mellitus

60 (15.3)

12 (11.9)

25 (16.9)

23 (16.0)

0.535

 Chronic heart failure

10 (2.5)

3 (3.0)

4 (2.7)

3 (2.1)

0.899

 Chronic renal disease

5 (1.3)

0 (0.0)

1 (0.7)

4 (2.8)

0.115

 Chronic obstructive pulmonary disease

17 (4.3)

5 (5.0)

9 (6.1)

3 (2.1)

0.229

Co-administered medications, n (%)

Assigned to Anakinra intervention

263 (66.9)

61 (60.4)

108 (73.0)

94 (65.3)

0.102

 Remdesivir

284 (72.3)

67 (66.3)

119 (80.4)

98 (68.1)

0.019

 Dexamethasone

387 (98.5)

100 (99.0)

146 (98.6)

141 (97.9)

0.771

 Low molecular weight heparin

253 (64.4)

59 (58.4)

104 (70.3)

90 (62.5)

0.262

Venous thromboembolic event, n (%)

8 (2.0)

3 (2.9)

2 (1.3)

3 (2.1)

0.673

Arterial thrombosis, n (%)

1 (0.3)

0 (0.0)

0 (0.0)

1 (0.7)

0.420

Laboratory values, median (Q1–Q3)

 White blood cells, /mm3

6380 (4570–8715)

7370 (5470–9640)

5390 (4190–7180)*,#

6880 (4670–9465)

 < 0.0001

 Lymphocytes, /mm3

770 (560–1050)

650 (500–900)

980 (710–1185)*,#

670 (520–900)

 < 0.0001

 Platelets, /mm3

208,000 (164,000–274500)

210,000 (175,000–273000)

186,000 (154,500–243000)*,#

226,000 (171,000–298500)

0.007

 C-reactive protein, mg/l

52.0 (25.6–102.4)

72.8 (25.4–114.6)

40.4 (21.4–76.8)*,#

63.0 (31.3–112.3)

0.003

 Interleukin-6, pg/ml

16.3 (6.4–40.9)

15.1 (5.8–33.1)

19.6 (7.2–45.7)

16.0 (6.1–43.8)

0.061

 Ferritin, ng/ml

635.9 (351.0–1146.4)

860.5 (446.0–1520.1)

533.6 (294.9–934.5)*

674.0 (310.6–1099.6)$

 < 0.0001

 D-dimers, mg/l

0.53 (0.32–0.95)

0.59 (0.33–1.16)

0.46 (0.28–0.77)*,#

0.55 (0.37–0.92)

0.040

 Serum soluble uPAR, ng/ml

7.9 (7.0–8.9)

7.7 (6.8–9.5)

8.0 (7.0–8.5)

8.0 (6.8–8.9)

0.835

 PaO2: FiO2

216 (172–275)

203 (154–250)

246 (199–293)*,#

203 (159–274)

 < 0.0001

  1. P-values of statistical significance are marked in bold
  2. SD standard deviation, SOFA sequential organ failure assessment, Q quartile, uPAR urokinase plasminogen activator receptor
  3. *p < 0.05 for comparison between adaptive and inflammopathic endotype
  4. #p < 0.05 for comparison between adaptive and coagulopathic endotype
  5. $p < 0.05 for comparison between inflammopathic and coagulopathic endotype